Galectin-9 alleviates acute graft-versus-host disease after haplo-hematopoietic stem cell transplantation by regulating regulatory T cell/effector T cell imbalance.

Nannan PangShabaaiti TudahongYuejie ZhuJiang HeChunxia HanGang ChenWeiguo WangJing Wang Jianbing Ding

Published in: Immunity, inflammation and disease (2024)

Galectin-9 may ameliorate aGVHD after haplo-HSCT by modulating Treg/Teffs balance and regulating the PI3K/AKT/mTOR pathway. Targeting Galectin-9 may hold potential value for the treatment of aGVHD.

Keyphrases

liver failure
acute myeloid leukemia
respiratory failure
signaling pathway
transcription factor
dendritic cells
drug induced
mouse model
intensive care unit
human health
drug delivery
hematopoietic stem cell